Aneurysmal subarachnoid hemorrhage (aSAH) frequently results in high mortality of 43% and permanent disability in 75% of survivors. Currently, calcium-channel blocker nimodipine is the only drug known to improve clinical outcome after subarachnoid hemorrhage. Therefore, new neuroprotective strategies are needed for aSAH patients. Numerous preclinical models of acute neuronal injury have confirmed noble gas xenon's neuroprotective properties. We have recently published first evidence that xenon provides neuroprotection also in humans. Xenon conferred neuroprotection by lessening the cerebral white matter injury in comatose survivors of cardiac arrest. Cerabral white matter is essential for normal neurocognitive function. Purpose of this randomized clinical drug trial is to investigate with brain magnetic imaging whether xenon lessens brain injury after aSAH as compared with a control group. The aim is to develop a new neuroprotective treatment for aSAH patients.

2020

2026